Kiniksa Pharmaceuticals Ltd. (KNSA)
Stock Price:
$17.24 USD
-1.20 (-6.48%)
Updated Oct 28, 2020 11:43 AM EDT - Market open
Key Info
| Market Cap |
1.17B |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-122.74M |
| Shares Out |
31.35M |
| EPS (ttm) |
-2.20 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 28, 2020 |
| Last Price |
$17.24 |
| Previous Close |
$18.43 |
| Change ($) |
-1.20 |
| Change (%) |
-6.48% |
| Day's Open |
18.01 |
| Day's Range |
17.11 - 18.28 |
| Day's Volume |
98,317 |
| 52-Week Range |
5.74 - 28.67 |
More Stats
| Market Cap |
1.17B |
| Enterprise Value |
919.30M |
| Earnings Date (est) |
Mar 11, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
31.35M |
| Float |
28.17M |
| EPS (basic) |
-2.19 |
| EPS (diluted) |
-2.20 |
| FCF / Share |
-2.02 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
3.30M |
| Short Ratio |
5.02 |
| Short % of Float |
11.70% |
| Beta |
-0.15 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
4.86 |
| Revenue |
n/a |
| Operating Income |
-124.27M |
| Net Income |
-122.74M |
| Free Cash Flow |
-117.12M |
| Net Cash |
250.79M |
| Net Cash / Share |
3.69 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-26.80% |
| ROE |
-46.71% |
| ROIC |
-80.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$37.00*
(114.68% upside)
Low
34.0
Current: $17.24
High
40.0
Target: 37.00
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | - | - | - | - |
| Operating Income | -170 | -108 | -65.40 | -24.00 |
| Net Income | -162 | -103 | -64.87 | -23.97 |
| Shares Outstanding | 54.05 | 29.55 | 1.81 | 0.26 |
| Earnings Per Share | -2.99 | -3.49 | -35.85 | -91.61 |
| Operating Cash Flow | -158 | -81.01 | -50.22 | -21.87 |
| Capital Expenditures | -3.20 | -5.29 | -0.07 | - |
| Free Cash Flow | -162 | -86.30 | -50.29 | -21.87 |
| Cash & Equivalents | 234 | 308 | 45.66 | 56.08 |
| Total Debt | 2.65 | - | - | - |
| Net Cash / Debt | 231 | 308 | 45.66 | 56.08 |
| Assets | 255 | 322 | 47.49 | 56.47 |
| Liabilities | 29.11 | 42.70 | 17.43 | 2.30 |
| Book Value | 225 | 279 | -89.71 | -25.73 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Kiniksa Pharmaceuticals Ltd. |
| Country |
Bermuda |
| Employees |
135 |
| CEO |
Sanj K. Patel |
Stock Information
| Ticker Symbol |
KNSA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: KNSA |
| IPO Date |
May 24, 2018 |
Description
Kiniksa Pharmaceuticals,, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and in Phase 1a clinical trial for the treatment of atopic dermatitis. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40/CD40L interaction, a central control node of T-cell-dependent, and B-cell-mediated humoral adaptive immunity. The company has a clinical collaboration with Kite Pharma, Inc. to evaluate investigational combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.